メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
中原 仁
内科学(神経)
ウェブサイト
https://k-ris.keio.ac.jp/html/100003279_ja.html
h-index
3506
被引用数
26
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2001
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(143)
類似のプロファイル
(6)
フィンガープリント
Jin Nakaharaが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Migraine
100%
Disease
88%
Multiple Sclerosis
83%
Ropinirole
78%
Myasthenia gravis
67%
Symptom
62%
Parkinson's Disease
50%
Clinical Trial
45%
Cholinergic Receptor Antibody
39%
Headache
38%
Placebo
38%
Fremanezumab
34%
Eculizumab
33%
Brain Hemorrhage
33%
Myositis
33%
Ravulizumab
33%
Aquaporin 4 Antibody
33%
Myelooptic Neuropathy
33%
Calcitonin Gene Related Peptide
33%
Amyotrophic Lateral Sclerosis
33%
Tolerability
32%
Adverse Event
29%
Galcanezumab
26%
Infection
25%
Olcegepant
22%
Drug Discovery
21%
Thymoma
20%
Disease Exacerbation
19%
Retrospective Study
19%
Tacrolimus
18%
Cohort Study
18%
Monoclonal Antibody
18%
Onset Age
18%
Immunosuppressive Agent
17%
Recurrent Disease
16%
4,4' Isopropylidenediphenol
16%
Atrial Fibrillation
16%
Prospective Cohort Study
16%
Postmarketing Surveillance
16%
Satralizumab
16%
Muscle Weakness
16%
Coronavirinae
16%
Yokukansan
16%
Myelin
16%
Drug Induced Headache
16%
Ofatumumab
16%
Lasmiditan
16%
Zilucoplan
16%
Immune Checkpoint Inhibitor
16%
Siponimod
16%
Keyphrases
Myasthenia Gravis
57%
Japan
54%
Neurology
50%
Multiple Sclerosis Treatment
39%
Fc Receptor
35%
Oligodendrocyte Precursor Cells
34%
Neurological Diseases
33%
Spreading Depolarization
33%
Alternative Interventions
33%
Anti-striational Antibodies
33%
Japanese Society of Neurology
33%
Ropinirole Hydrochloride
33%
Satralizumab
33%
Neuromyelitis Optica Spectrum Disorder (NMOSD)
33%
Oligodendrocyte Precursor Cell Differentiation
31%
Favorable Outcome
28%
Myocarditis
25%
Multiple Sclerosis Lesions
25%
Cerebral Blood Flow
25%
Myositis
24%
Thymoma
22%
Cell-based
20%
Tolerability
20%
Placebo
20%
Thymoma-associated Myasthenia Gravis
20%
Immunoglobulin Fc
20%
Migraine
20%
Clinical Characteristics
20%
Ischemic Stroke
19%
Gene-deficient Mice
19%
Myelin Basic Protein
18%
Hormone-like Effects
16%
Traditional Japanese Medicine
16%
Male Mice
16%
Galcanezumab
16%
Committee Member
16%
Retinal Migraine
16%
Nationwide Epidemiological Survey
16%
Radial Fiber
16%
Early Intervention
16%
Experimental Ischemia
16%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
16%
Postdrome
16%
Enteric Glial Cells
16%
Central Nervous System
16%
Research Education
16%
Systemic Aging
16%
Moderate to Severe
16%
Immunodeficiency
16%
IgLON5
16%
Medicine and Dentistry
Brain Ischemia
59%
Cerebral Hemorrhage
54%
Migraine
53%
Headache
52%
Multiple Sclerosis
50%
Neurology
44%
Neurologic Disease
37%
Apoplexy
37%
COVID-19
35%
Neuromyelitis Optica
33%
Parkinson's Disease
33%
Capillary
33%
Ravulizumab
33%
Atrial Fibrillation
33%
Disease
23%
Symptom
23%
Aquaporin 4 Antibody
20%
Fremanezumab
20%
Mild Cognitive Impairment
20%
Mechanical Thrombectomy
20%
Alzheimer's Disease
20%
Cholinergic Receptor Antibody
19%
Cohort Analysis
18%
Disease Modifying Therapy
18%
Erythrocyte
18%
Brain Infarction
18%
Blood Clot Lysis
18%
Thymoma
16%
Urology
16%
Retinal Migraine
16%
Galcanezumab
16%
Amyloid
16%
Neurotropin
16%
Mediobasal Hypothalamus
16%
Neuroinflammation
16%
Early Intervention
16%
Myasthenia gravis
16%
Thyroiditis
16%
Satralizumab
16%
Internal Carotid Artery
16%
Allogeneic Hematopoietic Stem Cell Transplantation
16%
Retrospective Study
16%
Direct Oral Anticoagulant
16%
Medication Overuse Headache
16%
Yokukansan
16%
Cognitive Defect
16%
Cerebral Cortex
16%
Transverse Myelitis
16%
Immune Checkpoint Inhibitor
16%
Angioimmunoblastic T-Cell Lymphoma
16%
